Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

BACKGROUND: Real-world clinical data to support the use of casirivimab–imdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimab–imdevimab treatment of mild to moderate COVID-19. METHODS: A ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Razonable, Raymund R., Pawlowski, Colin, O'Horo, John C., Arndt, Lori L., Arndt, Richard, Bierle, Dennis M., Borgen, Molly Destro, Hanson, Sara N., Hedin, Michelle C., Lenehan, Patrick, Puranik, Arjun, Seville, Maria T, Speicher, Leigh L., Tulledge-Scheitel, Sidna M., Venkatakrishnan, AJ, Wilker, Caroline G., Badley, Andrew D., Ganesh, Ravindra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404031/
https://www.ncbi.nlm.nih.gov/pubmed/34485873
http://dx.doi.org/10.1016/j.eclinm.2021.101102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404031/
https://www.ncbi.nlm.nih.gov/pubmed/34485873
http://dx.doi.org/10.1016/j.eclinm.2021.101102

Ejemplares similares